Document:

Exhibit 4.8

 Exhibit 4.8 
 SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”) dated as of July 15, 2008, among INTELSAT SATELLITE GALAXY 18, INC., a Delaware corporation (the “New Guarantor”), a
subsidiary of INTELSAT CORPORATION (or its successor), a Delaware corporation (the “Issuer”), the Issuer, the other Guarantors (as defined in the Indenture referred to herein) and THE BANK OF NEW YORK MELLON, as trustee under the
indenture referred to below (the “Trustee”). 
 W I T N E S S E T H: 
 WHEREAS the Issuer and the existing Guarantors have heretofore executed and delivered to the Trustee an Indenture (as amended, supplemented or otherwise
modified, the (“Indenture”) dated as of August 20, 2004, providing for the issuance of the Issuer’s 9% Senior Notes due 2014 (the “Notes”); 
 WHEREAS the Indenture provides that under certain circumstances the New Guarantor shall execute and deliver to the Trustee a supplemental indenture
pursuant to which the New Guarantor shall unconditionally guarantee all the Issuer’s obligations under the Notes and the Indenture pursuant to a Guarantee on the terms and conditions set forth herein; 
 WHEREAS the Indenture provides that in connection with this Supplemental Indenture, the Issuer shall have delivered to the Trustee an Officers’
Certificate and an Opinion of Counsel, and such Officers’ Certificate and Opinion of Counsel have been delivered to the Trustee on the date hereof; and 
 WHEREAS pursuant to Sections 901 and 903 of the Indenture, the Trustee and the Issuer are authorized to execute and deliver this Supplemental Indenture; 
 NOW THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt of which is hereby acknowledged, the New
Guarantor and the Trustee mutually covenant and agree for the equal and ratable benefit of the holders of the Notes as follows: 
 1.
Defined Terms. As used in this Supplemental Indenture, terms defined in the Indenture or in the preamble or recital hereto are used herein as therein defined, except that the term “Holders” in this Supplemental Indenture
shall refer to the term “Holders” as defined in the Indenture and the Trustee acting on behalf of and for the benefit of such Holders. The words “herein,” “hereof” and “hereby” and other words of
similar import used in this Supplemental Indenture refer to this Supplemental Indenture as a whole and not to any particular section hereof. 
 2. Agreement to Guarantee. The New Guarantor hereby agrees, jointly and severally with all existing Guarantors, to unconditionally guarantee the Issuer’s obligations under the Indenture and the Notes on the terms and subject to
the conditions set forth in the Guarantee and the Indenture, including but not limited to Article 12 of the Indenture, and to be bound by all other applicable provisions of the Indenture and the Notes applying to a Guarantor and to perform all
of the obligations and agreements of a Guarantor under the Indenture. 

 3. Notices. All notices or other communications to the New Guarantor shall be given as provided in
Section 106 of the Indenture. 
 4. Ratification of Indenture; Supplemental Indentures Part of Indenture. Except as expressly
amended hereby, the Indenture is in all respects ratified and confirmed and all the terms, conditions and provisions thereof shall remain in full force and effect. This Supplemental Indenture shall form a part of the Indenture for all purposes, and
every holder of Notes heretofore or hereafter authenticated and delivered shall be bound hereby. 
 5. Waiver of Claims. The New
Guarantor waives and shall not in any manner whatsoever claim or take the benefit or advantage of any rights of reimbursement, indemnity or subrogation or any other rights against the Issuer or any other Guarantor as a result of any payment by such
Guarantor under its Guarantee; 
 6. No Recourse Against Others. No past, present or future director, officer, employee, incorporator,
stockholder or agent of the New Guarantor, as such, shall have any liability for any obligations of the Company or any existing Guarantor under the Notes, any Guarantees, the Indenture or this Supplemental Indenture or for any claim based on, in
respect of, or by reason of, such obligations or their creation. Each Holder of the Notes by accepting a Note waives and releases all such liability. The waiver and release are part of the consideration for issuance of the Notes. Such waiver may not
be effective to waive liabilities under the federal securities laws and it is the view of the SEC that such a waiver is against public policy. 
 7. Governing Law. THIS SUPPLEMENTAL INDENTURE SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK. 
 8. The Trustee. The Trustee makes no representation as to the validity or sufficiency of this Supplemental Indenture. The recitals and statements herein are deemed to be those of the Issuer, the Guarantors and
the New Guarantor and not of the Trustee. Each signed copy shall be an original, but all of them together represent the same agreement. 
 9.
Counterparts. The parties may sign any number of copies of this Supplemental Indenture. Each signed copy shall be an original, but all of them together represent the same agreement. 
 10. Effect of Headings. The Section headings herein are for convenience only and shall not effect the construction thereof. 

 IN WITNESS WHEREOF, the parties hereto have caused this Supplemental Indenture to be duly executed as of
the date first above written. 
  

			
	INTELSAT SATELLITE GALAXY 18, INC.
		
	By:	 	/s/ Anita Beier
		 	 Name:     Anita Beier
 Title:
      Controller

  

			
	INTELSAT CORPORATION
		
	By:	 	/s/ Anita Beier
		 	 Name:     Anita Beier
 Title:
      Controller

  

			
	EACH OF THE ENTITIES LISTED ON
SCHEDULE I HERETO
		
	By:	 	/s/ Anita Beier
		 	 Name:     Anita Beier
 Title:
      Controller/Manager

  
  

			
	THE BANK OF NEW YORK MELLON, as Trustee
		
	By:	 	/s/ Carlos R. Luciano
		 	 Name:     Carlos R. Luciano
 Title:       Vice President

  
 [Supplemental
Indenture] 

 Schedule I 
 Guarantors 
  

			
	 Name
	  	 Jurisdiction of Incorporation

		
	 AccessPas, Inc.
	  	Delaware
		
	 Intelsat Asia Carrier Services, Inc.
	  	Delaware
		
	 PanAmSat Capital Corporation
	  	Delaware
		
	 PanAmSat Communications Carrier Services, Inc.
	  	California
		
	 PanAmSat Communications Japan, Inc.
	  	California
		
	 PanAmSat Communications Services, Inc.
	  	California
		
	 PanAmSat Europe Corporation
	  	Delaware
		
	 PanAmSat H-2 Licensee Corp.
	  	Delaware
		
	 PanAmSat India Marketing, L.L.C.
	  	Delaware
		
	 PanAmSat India, Inc.
	  	Delaware
		
	 PanAmSat International Holdings, LLC
	  	Delaware
		
	 PanAmSat International Sales, Inc.
	  	Delaware
		
	 PanAmSat International Systems Marketing, L.L.C.
	  	Delaware
		
	 Intelsat International Systems, LLC
	  	Delaware
		
	 PanAmSat Licensee Corp.
	  	Delaware
		
	 PanAmSat Satellite Galaxy 10R, Inc.
	  	Delaware
		
	 PanAmSat Satellite Galaxy 11, Inc.
	  	Delaware
		
	 PanAmSat Satellite Galaxy 12, Inc.
	  	Delaware
		
	 PanAmSat Satellite Galaxy 13, Inc.
	  	Delaware
		
	 PanAmSat Satellite Galaxy 14, Inc.
	  	Delaware
		
	 PanAmSat Satellite Galaxy 15, Inc.
	  	Delaware
		
	 PanAmSat Satellite Galaxy 16, Inc.
	  	Delaware
		
	 Intelsat Satellite Galaxy 17, Inc.
	  	Delaware
		
	 Intelsat Satellite IS 11, Inc.
	  	Delaware

			
		
	 PanAmSat Satellite Galaxy 1R, Inc.
	  	Delaware
		
	 PanAmSat Satellite Galaxy 3C, Inc.
	  	Delaware
		
	 PanAmSat Satellite Galaxy 3R, Inc.
	  	Delaware
		
	 PanAmSat Satellite Galaxy 4R, Inc.
	  	Delaware
		
	 PanAmSat Satellite Galaxy 5, Inc.
	  	Delaware
		
	 PanAmSat Satellite Galaxy 9, Inc.
	  	Delaware
		
	 PanAmSat Satellite HGS 3, Inc.
	  	Delaware
		
	 PanAmSat Satellite HGS 5, Inc.
	  	Delaware
		
	 PanAmSat Satellite Leasat F5, Inc.
	  	Delaware
		
	 PanAmSat Satellite PAS 10, Inc.
	  	Delaware
		
	 PanAmSat Satellite PAS 1R, Inc.
	  	Delaware
		
	 PanAmSat Satellite PAS 2, Inc.
	  	Delaware
		
	 PanAmSat Satellite PAS 3, Inc.
	  	Delaware
		
	 PanAmSat Satellite PAS 4, Inc.
	  	Delaware
		
	 PanAmSat Satellite PAS 5, Inc.
	  	Delaware
		
	 PanAmSat Satellite PAS 6B, Inc.
	  	Delaware
		
	 PanAmSat Satellite PAS 7, Inc.
	  	Delaware
		
	 PanAmSat Satellite PAS 8, Inc.
	  	Delaware
		
	 PanAmSat Satellite PAS 9, Inc.
	  	Delaware
		
	 PanAmSat Satellite SBS 6, Inc.
	  	Delaware
		
	 PanAmSat Services, Inc.
	  	Delaware
		
	 PAS International Employment, Inc.
	  	Delaware
		
	 PAS International, LLC
	  	Delaware
		
	 Intelsat Service and Equipment Corporation
	  	Delaware
		
	 Southern Satellite Corp.
	  	Connecticut
		
	 Southern Satellite Licensee Corporation
	  	Delaware
		
	 USHI, LLC
	  	DelawareAgreement between Dr. James Bender and ImmunoCellular Therapeutics, Ltd.

 EXHIBIT 10.1 
 

 
 August 18, 2008 
 James G. Bender, Ph.D. 
 3 Cloverdale 
 Rancho
Santa Margarita, CA 92688 
 Dear Jim 
 This
letter outlines the basis upon which ImmunoCellular Therapeutics, Ltd. (the “Company”) will engage you as its Vice President – Clinical Development. 
 1. Engagement. You will be engaged as Vice President – Clinical Development of the Company for the term and upon the terms and conditions set forth herein, and you accept such offer of engagement.
As the Vice President – Clinical Development, your duties will be those that are customary for a Vice President – Clinical Development of a company such as the Company, including without limitation assisting the Company in developing and
implementing clinical development plans and strategies for the Company’s product candidates, designing clinical trial protocols, securing and monitoring manufacturers for clinical supplies of product candidates, and communicating with the FDA
on all matters relating to the Company’s product candidates. You will report to the President and Chief Executive Officer of the Company. 
 2. Term. The term of your engagement will be one year, commencing on September 1, 2008, unless sooner terminated by you or the Company as set forth below in Section 7. 
 3. Commitment/Part-time Status. For the compensation provided in Section 4, you will set aside and commit a minimum (on average) of
two business days per week toward attending to the affairs of the Company as the Vice President – Clinical Development. The Company recognizes and agrees that, due to your part-time status, you may accept other employment or consulting
assignments concurrent with your engagement by the Company, which may include employment as an officer of publicly-traded companies and/or employment by other companies engaged in biotech or pharmaceutical research and development, provided that you
disclose such employment by any other company to the Company. 
 4. Compensation. As payment in full for your services during
the term of this Agreement, the Company shall compensate you as follows: 
 (a) The Company will pay you a monthly cash payment of $6,000 for
each month during the term of the Agreement; 
 (b) the Company will pay you a cash bonus of $10,000, provided that the Company’s IND
for its cancer stem cell vaccine product candidate (ICT-111) is cleared by no later than March 31, 2009 (the “CSC Milestone”); 
 

 

 James G. Bender, Ph.D. 
 August 18, 2008 
  Page
 2
 
  

 (c) the Company will pay you a cash bonus of $20,000, provided that the Company’s Phase II
trial for its dendritic cell-based vaccine product candidate (ICT-107) is initiated by no later than June 30, 2009 (the “Dendritic Cell Vaccine Milestone”); and 
 (d) the Company will grant you on the date of commencement of the term of this Agreement an option to purchase 66,000 shares of the Company’s common
stock (the “Option”). 
 The monthly cash compensation shall be paid on the last business day of each month, and the cash
compensation for achieving the CSC Milestone and Dendritic Cell Vaccine Milestone will be paid within 15 days of the Company achieving those respective milestones. The Option will have a seven-year term commencing on the date of grant; will vest at
the rate of 3,000 shares per month over the term of this Agreement as to 36,000 shares and will vest as to 10,000 shares upon achieving the CSC Milestone and 20,000 shares upon achieving the Dendritic Cell Vaccine Milestone; will have an exercise
price of the last reported trading price of the Company’s common stock on the OTC Bulletin Board; and will have such other terms and conditions as are included in the Company’s standard nonqualified stock option agreement under its 2006
Equity Incentive Plan (the “Plan”). The grant of the Option will be subject to the approval by the Company’s shareholders of an increase in the number of shares covered by the Plan to 3,400,000 shares. The Company will have no
obligation to pay you any of the cash compensation or vest any of the shares covered by the Option specified in this Section 4 with respect to a milestone that is not timely achieved for any reason, including a decision by the Company in its
sole discretion to abandon the development of ICT-107 or ICT-111 for any reason. 
 5. Expenses. The Company will promptly
reimburse you for all reasonable business expenses incurred by you in connection with the business of the Company in accordance with regular Company policy regarding the nature and amount of expenses and the maintenance and submission of receipts
and records necessary for the Company to document them as proper business expenses. These expenses shall include, without limitation, out-of-pocket telephone, facsimile, office supplies and authorized travel expenses (including mileage to
Cedars-Sinai Medical Center and to clinical manufacturer sites) but shall not include rent, utilities or similar overhead expenses incurred by you to maintain your office space. 
 6. Indemnity. To the extent permitted by California law, you agree to indemnify and hold the Company harmless from and against any
and all losses, damages, liabilities, costs, and expenses, including attorneys’ fees, arising from or attributable to or resulting from your gross negligence or willful misconduct in rendering the services. You warrant and represent that you
have full power and authority to enter into and perform this Agreement and that your performance of this Agreement will not violate the provisions of any other agreement to which you are a party. The Company agrees to indemnify and hold you harmless
from and against any and all claims, demands, causes of action, losses, damages, liability, costs and expenses, including attorneys fees arising out of your services hereunder, other than those arising from or attributable to or resulting from your
gross negligence or willful misconduct. The Company will name you as an officer on any policy of directors and officers liability insurance it secures throughout the term of your engagement. 

 James G. Bender, Ph.D. 
 August 18, 2008 
  Page
 3
 
  

 7. Termination. This Agreement and your rights and obligations hereunder shall,
under any of the following circumstances, terminate in advance of the time specified in Section 2 above, and you shall have the right to receive only your compensation that shall be accrued hereunder through the effective date of such
termination and shall have no right to receive any further compensation hereunder from and after the time of such termination. 
 7.1
Death or Disability. This Agreement and your duties hereunder shall terminate immediately upon your death or upon your becoming disabled and unable to perform your duties under this Agreement for more than a 30-day period.

 7.2 Termination by the Company. The Company may, at its option, terminate this Agreement and your duties hereunder by
written notice to you at any time without cause upon 15 days written notice to you. If you are terminated without cause, in addition to all accrued compensation, the Company shall grant you 50% of any unvested options as of the date of termination.
The Company may terminate this Agreement for Cause (as hereinafter defined) at any time upon written notice to you. “Cause” as used in this Agreement means that you, (i) after reasonable notice and warning, have failed to perform your
assigned duties as defined in this Agreement, with such failure to be determined by the Board of Directors, (ii) have materially breached any of the terms or conditions of this Agreement and have failed to correct such breach within 15 days
following written notice from the Company of such breach, or (iii) have been charged with a felony or any intentionally fraudulent act that materially damages, or may materially damage, the business or reputation of the Company. 
 7.3 Termination by the You. You may terminate this Agreement at any time upon written notice to the Company if the Company shall
have materially breached any of the provisions of this Agreement and has failed to correct such breach within 15 days following written notice from you of such breach. 
 8. Arbitration. In the event of any dispute under this Agreement, such dispute shall be resolved by binding arbitration with JAMS/ENDISPUTE in Los Angeles, California. The arbitrator shall be a retired
judge with at least five years of experience on the bench. This provision shall not be interpreted so as to require arbitration of claims that the state and/or Federal Courts of California have ruled may not be the subjects of compelled arbitration
in employment matters, nor shall it be interpreted so as to restrict any remedy, right of appeal or discovery device available to either party in a manner that violates the rulings of the state and/or Federal Courts of California with respect to
employment-related arbitration. This provision shall not be interpreted so as to preclude the making of reports to governmental offices, or to preclude either party from seeking injunctive or provisional relief in a court of appropriate jurisdiction
under such circumstances as may merit such relief. 

 James G. Bender, Ph.D. 
 August 18, 2008 
  Page
 4
 
  

 9. Confidentiality. While this Agreement is in effect and for a period of five years
thereafter, you shall hold and keep secret and confidential all “trade secrets” (within the meaning of California law) and shall use such information only in the course of performing your duties hereunder; provided, however, that with
respect to trade secrets, you shall hold and keep secret and confidential such trade secrets for so long as they remain trade secrets under California law. You shall maintain in trust all such trade secrets as the Company’s property, including,
but not limited to, all documents concerning the Company’s business, including your work papers, telephone directories, customer information and notes, and any and all copies thereof in your possession or under your control. Upon the expiration
or earlier termination of your employment with the Company, or upon request by the Company, you shall deliver to the Company all such documents belonging to the Company, including any and all copies in your possession or under your control.

 10. No Conflict. You represent that your performance of all the terms of this Agreement does not and will not breach any
agreement to keep in confidence any proprietary information acquired by you in confidence prior to the date of this Agreement. You have not brought and will not bring with you any equipment, supplies, facility or trade secret information of any
current or former employer which are not generally available to the public. 
 11. License and Assignment of Rights. You
acknowledge that all inventions, original works of authorship, developments, concepts, know-how, improvements or trade secrets which are made by you (solely or jointly with others) within the scope of and as part of your serving as the
Company’s Vice President – Clinical Development (collectively referred to herein as “Inventions”) are “works made for hire” (to the greatest extent permitted by applicable law) and are compensated by the consideration
provided by the Company as described in this Agreement, unless regulated otherwise by the mandatory law of the State of California. You also agree and warrant that you will not use or incorporate third party proprietary materials into Inventions,
disclose third party proprietary information to Company or knowingly engage in any activities or use any facilities in the course of providing services under this Agreement that could result in claims of ownership to any Inventions being made by any
third party. 
 12. Applicable Law. This Agreement shall be interpreted in accordance with the internal laws of the State of
California. 

 James G. Bender, Ph.D. 
 August 18, 2008 
  Page
 5
 
  

 We are delighted that you have agreed to serve as our Vice President – Clinical Development and
look forward to working with you to advance the Company’s clinical development programs. 
  

			
	Very truly yours,
	
	IMMUNOCELLULAR THERAPEUTICS, LTD.
		
	By:	 	 /s/ Manish Singh

		 	Manish Singh, Ph.D.
		 	President and Chief Executive Officer.

  

	
	Agreed to and Accepted as of this 26th day of August 2008.
	
	 /s/ James Bender

	James G. Bender, Ph.D.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00149-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00149-of-00352.parquet"}]]